The hopes of thousands of women living with an incurable secondary breast cancer (metastatic or state 4 breast cancer) could be raised by a University of Sheffield led clinical trial. With an estimated 35,000 people in the UK alone living with this incurable cancer, Professor Janet Brown leads the charge involving the administration of radium-223 and avelumab, drugs already in use for separate cancers, to 42 female patients with secondary breast cancer, now spreading throughout the body.
Although 99% of women diagnosed with breast cancer at State 1 go on to survive for five years or more on average post diagnosis, this success ratio precipitously drops to only 27% for patients diagnosed with a secondary breast cancer. Again 35,000 women reside in the UK with this condition.
Bringing Hope to Thousands
The idea now is that this University of Sheffield-led study could now bring hope to thousands of UK women residing with incurable secondary breast cancer, also known as metastatic or Stage 4 breast cancer.
Existing approved treatments are used in this study including radium-223 and avelumab. Radium-223, an isotope of radium with an...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).